Adenocarcinoma of the Pancreas
Conditions
Keywords
Pancreas, Resected
Brief summary
The current study seeks to further investigate the impact of Stereotactic Body Radiation Therapy following pancreatic resection with a close or positive margin. The investigators hope to improve local control, and through the use of a shortened treatment schedule, allow patients to begin systemic therapy earlier.
Detailed description
Radiation simulation will be done in Shadyside Radiation Oncology department Contrast-enhanced CT based simulation will be obtained prior to any adjuvant treatment (2-4 weeks post-op depending on healing). The target volume will be identified based on fiducial marker placement at time of surgery as well as a detailed discussion and image review with the operating surgeon. This are will be contoured on axial CT images obtained at 1.25 mm slice thickness. These volumes will then be reconstructed into a 3-dimensional image set for SBRT planning. Subjects will be simulated in the treatment position (supine with arms raised) on the CT scanner table the appropriate immobilization. Optiray® contrast will be administered intravenously at a flow rate of 2.5 mL/s. A helical CT scan of the abdomen will be acquired with intravenous contrast starting 30 seconds prior to CT acquisition. A 4D CT data acquisition for the same axial extent will be obtained. The images will then be electronically transferred from the CT workstation via DICOM3 to the appropriate treatment planning workstation in the department of radiation oncology. Based on axial CT images, fiducial marker placement, review of the pathology report, and a detailed discussion with the operating surgeon, contours will be drawn of the clinical target volume (CTV), which is defined as the area at risk for microscopic disease. The planning target volume (PTV) will be equivalent to the CTV unless motion is detected on the 4D motion study. If there is motion, the amount of motion in the superior-inferior, lateral, and anterior-posterior directions will be the margin given. Surrounding normal and critical structures will also be contoured by the treating radiation oncologist including the kidneys, liver, small bowel, spinal cord, and stomach if necessary. Stereotactic Body Radiotherapy Planning An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV. Careful evaluation of each plan will be conducted by the radiosurgical team to ensure that normal tissues and critical structures tolerances are maintained. The maximum dose (in Gy) within the treatment volume (MD), prescriptions dose (PD), and the ratio of MD/PD (as a measure of heterogeneity within the target volume), prescription isodose volume (PIV in mm3), tumor volume (TV in mm3), and the ratio of PIV/TV (as a measure of dose conformity of the treatment relative to the target) will be recorded. Evaluation during treatment The subjects will be carefully followed while on active treatment and post-treatment for 24 months, or until death. Treatment following SBRT All patients will have been seen in a multi-disciplinary pancreatic cancer clinic. As such, they will be set up with a medical oncologist. Following completion of SBRT as described in this protocol, the patient's medical oncologist may, at his/her discretion, administer systemic therapy according to the current standard of care or the UPMC pathways.
Interventions
RADIATIONStereotactic Body Radiation Therapy (SBRT)
An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV: 12 Gy x 3 fractions (36 Gy total)
Sponsors
David A. Clump, MD, PhD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically proven adenocarcinoma of the pancreas that has been resected with a close (\<2.5mm) or positive margin based on surgical and pathological findings. * Subjects will be staged according to the 2010 AJCC staging system (Appendix E) with pathologic stage T1-4, N0-1 being eligible; and have a primary tumor of the pancreas (i.e., pancreatic head, neck, uncinate process, body/tail * PTV must be encompassed in a reasonable SBRT portal as defined by the treating radiation oncologist * Karnofsky performance status \> 70 (ECOG 0-1) * Age \> 18 * Estimated life expectancy \> 12 weeks * Patient must have adequate renal function as defined by serum creatinine\<1.5mg/dl obtained within 28 days prior to registration * Patient must have adequate hepatic function as defined by total bilirubin \<1.5 xIULN(institutional upper limit of normal) and either SGOT or SGPT \<2.5xIULN, obtained within 28 days prior to registration. * Patient must be able to swallow enteral medications. Patient must not require a feeding tube. Patient must not have intractable nausea or vomiting, GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, or uncontrolled inflammatory bowel disease (Chron's, ulcerative colitis). * Ability to provide written informed consent * Patient must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, history of myocardial infarction or cerebrovascular accident within 3 months prior to registration, uncontrolled diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements. * Patient must not be pregnant because of the risk of harm to the fetus. Nursing women may participate only if nursing is discontinued, due to the possibility of harm to nursing infants from the treatment regimen. Women/men of reproductive potential must agree to use an effective contraception method.
Exclusion criteria
* Non-adenocarcinomas, adenosquamous carcinomas, islet cell carcinomas, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct, and ampullary carcinomas are not eligible. * Evidence of distant metastasis on upright chest x-ray (CXR), computed tomography (CT) or other staging studies * Subjects with recurrent disease * Prior radiation therapy to the upper abdomen or liver * Prior chemotherapy * Subjects in their reproductive age group should use an effective method of birth control. Subjects who are breast-feeding, or have a positive pregnancy test will be excluded from the study * Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the investigator * Concurrent serious infection * Previous or current malignancies of other histologies within the last 5 years, with the exception of cervical carcinoma in situ, adequately treated basal cell or squamous cell carcinoma of the skin, and treated low-risk prostate cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Local Progression-free Survival (LPFS) at 1-year | Up to 12 months | Percentage of patients that did not experience progressive disease (PD) in the target lesion. Death or development of distant disease was not regarded as an event. For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume. |
| Local Progression-free Survival (LPFS) at 2-years | Up to 24 months | Percentage of patients that did not experience progressive disease (PD) in the target lesion. Death or development of distant disease was not regarded as an event. For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume. |
| Local Progression-free Survival (LPFS) | Up to 24 months | Percentage of patients without disease progression in target lesion from time from enrollment until one month. Death or development of distant disease is not regarded as an event. For patients that undergo surgical resection, local progression will be defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume. |
| Regional Progression-free Survival (RPFS) | Up to 24 months | Time duration that patients that did not experience progressive disease (PD) in the target lesion. Death or development of distant disease was not regarded as an event. For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume. |
| Regional Progression-free Survival (RPFS) at 2-years | Up to 24 months | Percentage of patients that did not experience progressive disease (PD) in the target lesion. Death or development of distant disease was not regarded as an event. For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume. |
| Distant Metastasis-free Survival (DMFS) at 2 Years | Up to 24 months | Percentage of patients that did not experience distant metastasis. Death or development of distant disease was not regarded as an event. For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume. |
| Distant Metastasis-free Survival (DMFS) | Up to 24 months | Percentage of patients without distant disease metastasis (progression of disease beyond local target lesion). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Acute Toxicities Associated With SBRT | Up to 24 months | Percentage of patients that experienced acute toxicity (defined as toxicity occurring within 3 months of completion of SBRT). Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v 4. |
| Quality of Life (QoL) FACT-G | Up to 24 months (before treatment (baseline), shortly after neo-adjuvant treatment, shortly after surgery, shortly after SBRT, shortly after Adjuvant treatment) | The FACT-G is a 27 item questionnaire that assesses physical, social/family, emotional, and functional well-being, provided to patients and self-administered prior to SBRT, after completion of SBRT, and at each follow-up. The survey takes 5 minutes to complete and employs as five-point scale from 0 (not at all) to 4 (very much). Subscale scores added to obtain total score. Scoring range is between 0-108 points. Negatively worded items are reverse scored prior to summing so that higher subscale and total scores indicate better QoL. |
| Late Toxicities Associated With SBRT | Up to 24 months | Percentage of patients that experienced late toxicity (defined as toxicity occurring after 3 months of completion of SBRT). Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v 4. |
| 2-year Progression-free Survival (PFS) | Up to 24 months | Percentage of patients that did not experience disease progression at 2 years. For patients that undergo surgical resection, local progression will be defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume. |
| Time to Progression (TTP) | Up to 24 months | The time from enrollment to disease progression. For patients that undergo surgical resection, local progression will be defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume. |
| Overall Survival (OS) | Up to 24 months | The length of time from enrollment to confirmed death from any cause. |
| Overall Survival (OS) at 1-year | Up to 12 months | Percentage of patients alive at 1-year (death from any cause). |
| Overall Survival (OS) at 2-years | Up to 12 months | Percentage of patients alive at 2-years (death from any cause). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Stereotactic Body Radiotherapy Stereotactic Body Radiation Therapy (SBRT): An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV:
12 Gy x 3 fractions (36 Gy total) | 50 |
| Total | 50 |
Baseline characteristics
| Characteristic | Stereotactic Body Radiotherapy |
|---|---|
| Age, Continuous | 69.9 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 48 Participants |
| Sex: Female, Male Female | 24 Participants |
| Sex: Female, Male Male | 26 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 25 / 49 |
| other Total, other adverse events | 23 / 49 |
| serious Total, serious adverse events | 0 / 49 |
Outcome results
Primary
Distant Metastasis-free Survival (DMFS)
Percentage of patients without distant disease metastasis (progression of disease beyond local target lesion).
Time frame: Up to 24 months
Population: Patients that received study treatment per protocol and were evaluable for response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stereotactic Body Radiotherapy | Distant Metastasis-free Survival (DMFS) | 21 percentage of participants |
Primary
Distant Metastasis-free Survival (DMFS) at 2 Years
Percentage of patients that did not experience distant metastasis. Death or development of distant disease was not regarded as an event. For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
Time frame: Up to 24 months
Population: Patients that received study treatment per protocol and were evaluable for response.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stereotactic Body Radiotherapy | Distant Metastasis-free Survival (DMFS) at 2 Years | 49.69 percentage of participants |
Primary
Local Progression-free Survival (LPFS)
Percentage of patients without disease progression in target lesion from time from enrollment until one month. Death or development of distant disease is not regarded as an event. For patients that undergo surgical resection, local progression will be defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
Time frame: Up to 24 months
Population: Patients that received study treatment per protocol and were evaluable for response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stereotactic Body Radiotherapy | Local Progression-free Survival (LPFS) | NA percentage of participants |
Primary
Local Progression-free Survival (LPFS) at 1-year
Percentage of patients that did not experience progressive disease (PD) in the target lesion. Death or development of distant disease was not regarded as an event. For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
Time frame: Up to 12 months
Population: Patients that received study treatment per protocol and were evaluable for response.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stereotactic Body Radiotherapy | Local Progression-free Survival (LPFS) at 1-year | 85 percentage of participants |
Primary
Local Progression-free Survival (LPFS) at 2-years
Percentage of patients that did not experience progressive disease (PD) in the target lesion. Death or development of distant disease was not regarded as an event. For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
Time frame: Up to 24 months
Population: Patients that received study treatment per protocol and were evaluable for response.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stereotactic Body Radiotherapy | Local Progression-free Survival (LPFS) at 2-years | 78.12 percentage of participants |
Primary
Regional Progression-free Survival (RPFS)
Time duration that patients that did not experience progressive disease (PD) in the target lesion. Death or development of distant disease was not regarded as an event. For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
Time frame: Up to 24 months
Population: Patients that received study treatment per protocol and were evaluable for response.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stereotactic Body Radiotherapy | Regional Progression-free Survival (RPFS) | NA months |
Primary
Regional Progression-free Survival (RPFS) at 2-years
Percentage of patients that did not experience progressive disease (PD) in the target lesion. Death or development of distant disease was not regarded as an event. For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
Time frame: Up to 24 months
Population: Patients that received study treatment per protocol and were evaluable for response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stereotactic Body Radiotherapy | Regional Progression-free Survival (RPFS) at 2-years | 72.2 percentage of participants |
Secondary
2-year Progression-free Survival (PFS)
Percentage of patients that did not experience disease progression at 2 years. For patients that undergo surgical resection, local progression will be defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
Time frame: Up to 24 months
Population: Patients that received study treatment per protocol and were evaluable for response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stereotactic Body Radiotherapy | 2-year Progression-free Survival (PFS) | 32.79 percentage of participants |
Secondary
Acute Toxicities Associated With SBRT
Percentage of patients that experienced acute toxicity (defined as toxicity occurring within 3 months of completion of SBRT). Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v 4.
Time frame: Up to 24 months
Population: Patients that received study treatment per protocol and experienced acute grade 3 þ radiation toxicity.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stereotactic Body Radiotherapy | Acute Toxicities Associated With SBRT | 4.1 percentage of participants |
Secondary
Late Toxicities Associated With SBRT
Percentage of patients that experienced late toxicity (defined as toxicity occurring after 3 months of completion of SBRT). Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v 4.
Time frame: Up to 24 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stereotactic Body Radiotherapy | Late Toxicities Associated With SBRT | 0 percentage of participants |
Secondary
Overall Survival (OS)
The length of time from enrollment to confirmed death from any cause.
Time frame: Up to 24 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stereotactic Body Radiotherapy | Overall Survival (OS) | 18 months |
Secondary
Overall Survival (OS) at 1-year
Percentage of patients alive at 1-year (death from any cause).
Time frame: Up to 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stereotactic Body Radiotherapy | Overall Survival (OS) at 1-year | 68 percentage of participants |
Secondary
Overall Survival (OS) at 2-years
Percentage of patients alive at 2-years (death from any cause).
Time frame: Up to 12 months
Population: Participants enrolled in study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stereotactic Body Radiotherapy | Overall Survival (OS) at 2-years | 39.95 percentage of participants |
Secondary
Quality of Life (QoL) FACT-G
The FACT-G is a 27 item questionnaire that assesses physical, social/family, emotional, and functional well-being, provided to patients and self-administered prior to SBRT, after completion of SBRT, and at each follow-up. The survey takes 5 minutes to complete and employs as five-point scale from 0 (not at all) to 4 (very much). Subscale scores added to obtain total score. Scoring range is between 0-108 points. Negatively worded items are reverse scored prior to summing so that higher subscale and total scores indicate better QoL.
Time frame: Up to 24 months (before treatment (baseline), shortly after neo-adjuvant treatment, shortly after surgery, shortly after SBRT, shortly after Adjuvant treatment)
Population: Patients that completed FACT-G Quality of Life surveys.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Emotional well-being (EWB) - Shortly after neo-adjuvant | 22 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Total score - Shortly after neo-adjuvant | 94 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Total score - Shortly after surgery | 85 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Physical well-being (PWB) - Before treatment (baseline) | 24 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Physical well-being (PWB) - Shortly after neo-adjuvant treatment | 25 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Physical well-being (PWB) - Shortly after surgery | 24 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Physical well-being (PWB) - Shortly after SBRT | 23 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Physical well-being (PWB) - Shortly after adjuvant treatment | 18 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Social/family well-being (SWB) - Before treatment (baseline) | 26 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Social/family well-being (SWB) - Shortly after neo-adjuvant treatment | 28 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Social/family well-being (SWB) - Shortly after surgery | 25 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Social/family well-being (SWB) - Shortly after SBRT | 26 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Social/family well-being (SWB) - Shortly after adjuvant treatment | 17 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Emotional well-being (EWB) - Before treatment (baseline) | 17 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Emotional well-being (EWB) -Shortly after surgery | 20 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Emotional well-being (EWB) -Shortly after SBRT | 21 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Emotional well-being (EWB) - Shortly after adjuvant treatment | 14 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Functional well-being (FWB) - Before treatment (baseline) | 14 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Functional well-being (FWB) - Shortly after neo-adjuvant | 20 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Functional well-being -Shortly after surgery | 22 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Functional well-being (FWB) Shortly after SBRT | 13 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Functional well-being (FWB) Shortly after adjuvant treatment | 17 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Total score - Before treatment (baseline) | 83 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Total score - Shortly after SBRT | 78 score on a scale |
| Stereotactic Body Radiotherapy | Quality of Life (QoL) FACT-G | Total score - Shortly after adjuvant treatment | 64 score on a scale |
Secondary
Time to Progression (TTP)
The time from enrollment to disease progression. For patients that undergo surgical resection, local progression will be defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
Time frame: Up to 24 months
Population: Patients that received study treatment per protocol and were evaluable for response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stereotactic Body Radiotherapy | Time to Progression (TTP) | 12 months |